{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:20:23Z","timestamp":1787548823870,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is currently no standardized treatment strategy for monoclonal immunoglobulin deposition disease, and anti-plasma cell therapy is considered an effective method for treating patients with this pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 72 patients with biopsy-confirmed monoclonal immunoglobulin deposition \u00addisease from 2005 to 2025, divided by first-line therapy into bortezomib\/dexamethasone (BD, n = 37) and thalidomide\/\u00addexamethasone (TD, n = 35) groups. The bortezomib\/dexamethasone group was further divided into those who received autologous stem cell transplantation (bortezomib\/dexamethasone with autologous stem cell transplantation, n = 8) and those who did not (bortezomib\/dexamethasone-only, n = 29). Efficacy was analyzed in evaluable patients, and risk factors for renal survival, time to next treatment, and overall survival were assessed in the entire cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The two groups had comparable baseline characteristics. The entire bortezomib\/dexamethasone cohort showed superior rates of hematological complete response\/very good partial response (63% vs. 46%), and renal complete response\/very good partial response (57% vs. 32%) than the thalidomide\/dexamethasone group, with superior 5-year renal survival (73% vs. 51%) and a favorable trend in 5-year overall survival (85% vs. 64%). The bortezomib\/dexamethasone-only subgroup showed a significantly higher complete response rate (52% vs. 25%) and favorable trends in 5-year renal survival (74% vs. 51%) and overall survival (79% vs. 64%) compared with thalidomide\/dexamethasone. In the 8 autologous stem cell transplantation patients, the hematological complete response rate increased from 25% post-induction to 75% post-transplant. Multivariate analysis identified chronic kidney disease (CKD) stage \u22643, hematological complete response\/very good partial response, and the bortezomib\/dexamethasone regimen as independent protective factors for renal survival. Regarding safety, neurotoxicity occurred in 19% of bortezomib\/dexamethasone patients and in 29% of thalidomide\/dexamethasone patients, while anemia and peripheral edema were more frequent in the thalidomide\/dexamethasone group; no treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The bortezomib\/dexamethasone regimen yields deeper hematological response and improved renal survival in monoclonal immunoglobulin deposition disease patients. Bortezomib\/dexamethasone followed by autologous stem cell transplantation is recommended for transplant-eligible patients, while bortezomib\/dexamethasone alone remains effective for those who are ineligible, which supports bortezomib\/dexamethasone as first-line therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag144","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:43:19Z","timestamp":1779277399000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease"],"prefix":"10.1093","author":[{"given":"Jianan","family":"Jiang","sequence":"first","affiliation":[{"name":"Southeast University School of Medicine , Nanjing 210009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencui","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing 210016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing 210016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Guo","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing 210016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing 210016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-9426","authenticated-orcid":false,"given":"Xianghua","family":"Huang","sequence":"additional","affiliation":[{"name":"Southeast University School of Medicine , Nanjing 210009 ,","place":["China"]},{"name":"National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University , Nanjing 210016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"2026082400550018100_aajag144-B1","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082400550018100_aajag144-B2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ki.1994.355","article-title":"Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains","volume":"46","author":"Preud'homme","year":"1994","journal-title":"Kidney Int"},{"key":"2026082400550018100_aajag144-B3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2215\/CJN.01730506","article-title":"Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy","volume":"1","author":"Ronco","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082400550018100_aajag144-B4","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","article-title":"Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors","volume":"42","author":"Pozzi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026082400550018100_aajag144-B5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2215\/CJN.08640811","article-title":"Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution","volume":"7","author":"Nasr","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082400550018100_aajag144-B6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.24756","article-title":"Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease","volume":"92","author":"Mohan","year":"2017","journal-title":"Am J Hematol"},{"key":"2026082400550018100_aajag144-B7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.7326\/0003-4819-76-3-112-6-455","article-title":"Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis","volume":"112","author":"Buxbaum","year":"1990","journal-title":"Ann Intern Med"},{"key":"2026082400550018100_aajag144-B8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/bjh.19956","article-title":"Diagnosis and management of monoclonal gammopathy of renal significance: a British society for haematology good practice paper","volume":"206","author":"Pinney","year":"2025","journal-title":"Br J Haematol"},{"key":"2026082400550018100_aajag144-B9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12185-011-0829-4","article-title":"Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease","volume":"93","author":"Fujita","year":"2011","journal-title":"Int J Hematol"},{"key":"2026082400550018100_aajag144-B10","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood"},{"key":"2026082400550018100_aajag144-B11","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7485695","article-title":"Treatment of light chain deposition disease using bortezomib-based regimen followed by thalidomide-based regimen in a Saudi male","volume":"2016","author":"Adamu","year":"2016","journal-title":"Case Rep Nephrol"},{"key":"2026082400550018100_aajag144-B12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026082400550018100_aajag144-B13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/ajh.23235","article-title":"Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy","volume":"87","author":"Jimenez-Zepeda","year":"2012","journal-title":"Am J Hematol"},{"key":"2026082400550018100_aajag144-B14","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3324\/haematol.2023.284520","article-title":"Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the chronic malignancies working party of the European society for blood and marrow transplantation","volume":"109","author":"Garderet","year":"2024","journal-title":"Haematologica"},{"key":"2026082400550018100_aajag144-B15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/bloodadvances.2020001553","article-title":"Daratumumab in light chain deposition disease: rapid and profound hematological response preserves kidney function","volume":"4","author":"Milani","year":"2020","journal-title":"Blood Adv"},{"key":"2026082400550018100_aajag144-B16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2021.1971192","article-title":"Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"key":"2026082400550018100_aajag144-B17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"key":"2026082400550018100_aajag144-B18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"key":"2026082400550018100_aajag144-B19","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00277-024-05911-9","article-title":"Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies","volume":"104","author":"Cassano Cassano","year":"2025","journal-title":"Ann Hematol"},{"key":"2026082400550018100_aajag144-B20","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/jco.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026082400550018100_aajag144-B21","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"2026082400550018100_aajag144-B22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082400550018100_aajag144-B23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"},{"key":"2026082400550018100_aajag144-B24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1096\/fj.05-4870fje","article-title":"Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts","volume":"20","author":"Fineschi","year":"2006","journal-title":"FASEB J"},{"key":"2026082400550018100_aajag144-B25","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1016\/s2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026082400550018100_aajag144-B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag144\/70766740\/aajag144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag144\/70766740\/aajag144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:55:07Z","timestamp":1787547307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag144\/8768998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag144","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"aajag144"}}